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Abstract
Diabetes mellitus is associated with a reduced responsiveness to
catecholamines.

The reduced responsiveness may be attributable to a

reduction in beta-adrenoceptor sensitivity to catecholamines.
Radioligand binding studies demonstrate that chemically-induced diabetes reduces beta-adrenoceptor number without altering betaadrenoceptor drug binding affinities.

The present study re-examines

the effect of chronic (10 weeks) streptozotocin-induced diabetes in
the rat on beta-adrenoceptor drug binding affinity, using pharmacological techniques, to test the results of the binding studies.
The study employed two different methods:

partial irreversible recep-

tor blockade and the use of a partial agonist, to determine betaadrenoceptor agonist binding affinity and the method of competitive
antagonism to determine beta-adrenoceptor antagonist binding affinity.
Diabetes produced no significant differences in the dissociation
constants (l/affinity) for isoproterenol or for metaproterenol and no
significant differences in the pAz values for timolol maleate which
correlates to antagonist binding affinity.

Therefore, the study con-

firms the results of radioligand binding studies by using intact
tissue that diabetes does not alter beta-adrenoceptor drug binding
affinity in cardiac tissue.
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Diabetes mellitus is associated with a higher incidence of morbidity and mortality from cardiac disease than is present in the nondiabetic population (Kannel, 1979).

The data suggest that diabetes is

another discrete cause of congestive heart failure and that a cardiomyopathy is associated with diabetes, as a result of small vessel
disease, metabolic disorders, or both.

These disorders produce struc-

tural, functional, and biochemical changes in cardiac tissue (Ledet et
al., 1979).
Vascular disease associated with diabetes mellitus is well known
(Colwell~

al., 1979; Zoneraich

~al.,

1980).

However, diabetes may

produce a cardiopathy which is independent of vascular abnormalities.
In some cases, pathological studies of diabetic human hearts revealed
patent and atherosclerosis-free large coronary arteries (Hamby
1974).

~al,

Autopsies failed to detect significant obstructive disease of

the proximal arteries in some diabetic patients succumbing to heart
failure

(Regan~

al., 1977).

al., 1974; Miller, 1979;

Several experimental studies

Fein~

(Regan~

al., 1980; Penpargkul et al., 1980;

Vadlamudi et al., 1982) demonstrated impaired muscle function in both
chronic (greater than two weeks duration) and acute (usually less than
one week) chemically-induced diabetic rat hearts.

Some of these stu-

dies, also, suggest that diabetes decreases diastolic ventricular
compliance and the rate of relaxation (Regan :=..t al., 1974; Miller,
1979).

Streptozotocin-induced diabetes in the rat produces no signifi-

cant cardiac macrovascular disease (Chobanian
cardiac performance (Vadlamudi et al., 1982).

~al.,

1982), but impairs

These results suggest

that diabetes produces a direct alteration of the rat myocardium.
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A possible consequence of diabetic cardiopathy might be the
appearance of an

~ltered

sensitivity to the positive chronotropic and

positive inotropic effects of catecholamines (Cavaliere et al., 1980).
Experimental and clinical evidence suggests that diabetes may also
alter autonomic control of the myocardium.

Clinically, diabetic

patients exhibit a supersensitivity to cholinomimetic agents and to
catecholamines; the supersensitivity to the former is more pronounced
than to the latter (Lloyd-Mostyn and Watkins, 1975).

However, hearts

of two week streptozotocin-diabetic rats are subsensitive to both acetylcholine and catecholamines (Foy and Lucas, 1978).

Diabetic hearts

are less sensitive than non-diabetic hearts to carbachol 100 days
after . the induction of diabetes by streptozotocin, but they are supersensitive to carbachol at 180 days (Vadlamudi and McNeill, 1983).

The

supersensitivity observed both clinically and experimentally may be
related to the well known autonomic neuropathy associated with chronic
diabetes in humans (Watkins and Edmonds, 1983) and experimentally
diabetic rats

(Schmidt~

al., 1981).

The possible mechanism for

diabetes-induced cardiac subsensitivity is less clearly defined.
The effect of diabetes on cardiac responsiveness to catecholamines may vary with the severity of the diabetic state, although the
evidence is not at all clear.

In humans, tachycardia is often asso-

ciated with chronic diabetes, primarily due to vagal dysfunction
(Lloyd-Mostyn and Watkins, 1975).

In the rat, experimental chronic

diabetes most often produces bradycardia (Savarese and Berkowitz,
1980), but acute diabetes has no effect on heart rate.

A reduction

3

in beta-adrenoceptor sensitivity to catecholamines can explain the
lowered heart rate of the diabetic rat.

~-adrenoceptor

number or

density and drug-binding affinity determine beta-adrenoceptor sensitivity to catecholamines.

Radioligand binding techniques provide a

method of assessing beta-adrenoceptor density (Bmax) and drug-binding
affinity.

Diabetes produced a 28% decrease in beta-adrenoceptor den-

sity accompanied a 24% in heart rate without any alterations in antagonist (H3-dihydroalprenolol) binding affinity (Savarese and
Berkowitz, 1980).
Ingebretson

~al.

(198la),

Heyliger~

al.(1982), and

Ramanadham and Tenner (1983) confirm that diabetes decreased betaadrenoceptor density without altering antagonist affinity in rat
hearts.

No direct in vitro studies of the positive chronotropic

responsiveness of diabetic hearts to catecholamines have been performed.

Diabetes had no effect on competitive [3H]-DHA binding curves

by isoproterenol in membrane homogenates suggesting that agonist
binding affinity is unaltered

(Williams~

al., 1983).

However, no

studies on beta-adrenoceptor drug-binding affinities of intact tissue
have been performed.
Diabetes alters the mechanical function of the heart, as previously indicated, but apparently not the inotropic responsiveness to
catecholamines.

Ingebretson

~al.

(198lb) reported that acute

alloxan diabetes had no effect on the inotropic response of isolated
rat hearts to isoproterenol.

Heyliger

~

al. (1982) report that

diabetic papillary muscle exhibited a decreased ability to respond to
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beta-adrenergic stimulation, based upon the rates of tension development (positive dF/dt) and relaxation (negative dF/dt).

In control

preparations, isoproterenol produced marked increases in both the
positive dF/dt and negative dF/dt, whereas, in diabetic preparations,
the positive dF/dt was unresponsive to isoproterenol and the negative
dF/dt responded only marginally.
The questions of cardiac beta-adrenoceptor sensitivity in experimental diabetes has not been fully resolved.

The depressed responses

of the papillary muscle preparations from diabetic rats discussed
above may be explained as an alteration in beta-adrenoceptor sensitivity.

A reduced beta-adrenoceptor sensitivity can also explain

the bradycardia which accompanies experimental diabetes.

As pre-

viously shown, diabetes reduces beta-adrenoceptor sensitivity by
reducing beta-adrenoceptor density.

The possibility of reducing beta-

adrenoceptor sensitivity by the reduction of agonist binding affinity
needs to be reexamined.

The functional differences between agonist

and antagonist binding kinetics

(Weiland~

al., 1979; 1980) suggest

that diabetes may alter agonist binding affinity without altering
antagonist binding affinity.

Agonist-induced desensitization of

beta-adrenoceptors may reduce the apparent agonist binding affinity
without altering antagonist binding affinity

(Tse~

Hoffman and Lefkowitz, 1980; Harden, 1983).

Response is a function of

al., 1978;

agonist binding, complete assessment of beta-adrenoceptor sensitivity
requires characterization of agonist binding affinity
1978).

(Wessels~

al.,
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The original hypothesis of the present study stated that diabetes
reduces agonist affinity for beta-adrenoceptors in the rat heart.
The recent observations by

Williams~

al., 1983) that eight weeks of

streptozotocin-induced diabetes had no effect on beta-adrenoceptor
agonist binding lead to a re-evaluation of the hypothesis.

The pre-

sent study reexamines the recent findings that diabetes does not alter
beta-adrenoceptor drug-binding affinity using alternative experimental
techniques.

A decrease in beta-adrenoceptor number plays a major role

in the diabetic subsensitivy to catecholamines and can help to explain
the bradycardia which accompanies experimental diabetes in the rat;
however, the possible role of a reduction in agonist affinity remains
unclear.

This study provides a systematic determination of beta-

adrenoceptor agonist and antagonist affinities in normal and experimentally-diabetic rat atria.

The use .of isolated atria allows

characterization of both the positive

~ronotropic

and positive

inotropic effects of catecholamines.
Several pharmacological procedures exist for the determination of
agonist affinity.

The availability of the beta-adrenoceptor antago-

nist Ro 03-7894 (1-(5-chloroacetylaminobenzfuran-2-yl)-2-isopropylaminoethanol), which acts irreversibly and selectively with
beta-adrenoceptors (Nicholson and Broadley, 1978; Rankin and Broadley,
1982) allows pharmacological characterization by the method of partial
irreversible receptor blockade (Furchgott and Bursztyn, 1967).

The

method of partial agonists described by Waud (1969) affords an alternative technique for the determination of agonist afinity for beta-
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adrenoceptors.

Construction of Schild plots, using several

concentrations of a competitive beta-adrenoceptor antagonist, allows
calculation of antagonist affinities, expressed as pA2 values.

The

present study statistically compares agonist dissociation constants
(!/Affinity) or antagonist pA2 (-log KB) values from control and
diabetic rat atria tests for affinity changes produced by diabetes.

LITERATURE REVIEW
Induction of Diabetes

.

Alloxan and streptozotocin are the most extensively used agents
for induction of diabetes because the diabetogenic dose is 1/4 to 1/5
times the lethal dose (Grodsky

~al.,

1982).

The dose varies con-

siderably among species and with the age and metabolic state of the
animal.

Both alloxan and streptozotocin produce beta-cell necrosis in

the rat (Ganda

~al.,

1976).

Streptozotocin appears to be more

selective than alloxan (Rerup, 1970); the possible reason for this
might be the high capacity of beta cells to accumulate this agent
(Srivasta

~al.,

1982).

Streptozotocin models are thought to be more

relevant to the human diabetic state than alloxan models, due to metabolic profiles, enzyme concentrations, and histopathology.

Alloxan-

induced diabetes is more ketotic than streptozotocin-induced diabetes
(Mansford and Opie, 1968).
Due to its instability, streptozotocin is dissolved in 0.1 M
citrate buffer, pH 4.5 just prior to injection.

Streptozotocin is
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optimally stable at around pH 4 (Rerup, 1970) and its biological halflife is about 5 minutes, which necessitates an intravenous injection.
For induction of diabetes, streptozotocin is conventionally administered as a single injection (Like and Rossini, 1976).

Maximal ele-

vation of plasma glucose is achieved with 60 mg/kg (Ganda

~al.,

1976),

but significant increases in plasma glucose occur with 40

mg/kg.
Pharmacological vs. Radioligand Binding Techniques for Assessing
Receptor Characteristics
Recent reviews (Furchgott, 1978; Tallarida 1981; 1982) compare
the strengths and drawbacks of pharmacological and radioligand binding
procedures.

In summary, both procedures estimate drug-binding affini-

ties for a specific receptor and the rate and extent of receptor inactivation by irreversible antagonists.

However, only a radioligand

yields an estimate of receptor number or density (Bmax), whereas, a
pharmacological procedure permits evaluation of the relative efficacies of agonists acting upon a receptor to produce a response.
Radioligand binding procedures require the demonstration of specific
binding to tissue sites and no effect is measured.
defined differently in each technique.

Thus, receptor is

The pharmacological definition

of receptor has an "operational" meaning, i.e., drug-binding produces
an effect; whereas the radioligand binding technique requires
demonstration of a specific binding site or receptor.

Typically,

pharmacological procedures employ isolated tissue and radioligand
techniques use membrane fractions.

8

The pA2 and the Schild Plot
The Schild regression (Arunlakshana and Schild, 1959), theoretically, can yield the binding constant (KB) of a competitive antagonist
for a drug receptor using pharmacological techniques.

The x-intercept

of the Schild regression (pA2) provides an estimate of the binding
constant under certain conditions (Furchgott, 1972).
important in classifying receptors (Kenakin, 1982).

The pA2 is
The pA2 is

defined as the negative logarithm of the molar concentration of an
antagonist which reduces the effect of a dose of agonist by half
(Tallarida

~al.,

1979).

Figure a shows a Schild plot constructed

from cumlative dose-response curves in the presence of various concentrations of a competitive antagonist (see figure b).
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Figure a:

Theoretical Sc hjlJ Plot Depicting the 'pA Value
2

'

~

0

~

0

- log(Antagonist Concentration)

A theoretical Schild Plot, log (DR-1) versus -log [B], consisting
of a straight line of slope unity and an x-intercept (-log KB or pA ).
Several antagonist concentrations [B] yield the points for drawing the
line.

10

Figure b:

Cumulative Dose-Response Curves of a Full Agonist Illustrating
Competitive Antagonism

A

A1

Agonist Concentration

A'

I

As the antagonist concentration [B] increases, the dose-response
curve shifts to the right. The degree of the shift is indicated by
the dose ratio (DR) of A'/A. Thus, it takes a higher agonist concentration, A', to produce the same effect in the presence of antagonist
than the concentration A, producing the same effect in the absence of
antagonist. All curves achieve the same maximum effect, since the
antagonism is surmountable and the curves should be parallel due to
the competitiveness of the antagonism. The dose ratios (DR), converted to log (DR-1), for each antagonist concentration [B], expressed
as -log [B] yield points for a Schild plot.
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Based upon the occupation theory (Furchgott, 1972) stating that
the effect produced by an agonist depends upon the concentration of
the agonist-receptor complex, the following equation can be derived:
[A'] - 1

TAJ

=fil

or

log (DR-1)

=-

log KB + log [B]

KB

where DR (dose ratio) is defined as [A']/[A], Bis the antagonist
concentration and KB is the equilibrium binding constant of the antagonist.
A plot of log (DR-1) versus the negative logarithm of the antagonist concentration (-log [B]) in molar units yields a straight line
with a slope of 1 (Figure a).

The x-intercept yields the pAz values

or the negative logarithm of the equilibrium binding constant of the
antagonist.
Agonist Affinity (l/KA):
Blockade

Method of Partial Irreversible Receptor

The method of partial irreversible receptor blockade (Furchgott
and Bursztyn, 1967) avoids the assumption of classical receptor theory
that the full effect requires full receptor occupancy.

The method

requires an antagonist that combines with the same receptor as the
agonist.

The antagonist, by combining irreversibly and selectively

with the receptor, reduces the free receptor population. If a sufficient number or receptors become inactivated, then the maximum
response diminishes, based upon .the occupation theory.
Figure c illustrates the dose-response curves obtained from an
idealized experiment using partial irreversible receptor blockade.

12

Partial irreversible receptor blockade displaces the dose response
curve to the right and reduces the maximum response in a dosedependent manner.

This method requires proper washout of the antago-

nist to achieve an equilibrium receptor blockade.

~

Figure c:

Equal Response to a Full Agonist in the Absence and Presence
of Irreversible Receptor Blockade

E

Agonist Concentration

Curve II represents the dose-response curve for agonist after
washout of the irreversible antagonist. Curve II does not achieve the
maximum response of curve I (pre-antagonist). The irreversible antagonist
displaces the dose-response curve to the right. Equiactive effects from
the linear portion of each line E and E etc., yield pairs of agonist
concentrations, (A_ ,A' 1 ), (A7 , A1 1 ), etc.4 which produce each effect.
Plotting the reciptccaI valu~s of 2each pair of agonist concentration,
(1/A ,1/A' ), etc. yields a straight-line.
1
1
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By taking equiactive effects lying on the linear portions of both
curves (see figure c), one obtains pairs of agonist concentrations
corresponding to each effect; i.e., (A1, A'1), (Az, A'z), •••• (AN,
A'N)•

Plotting each pair of agonist concentrations, expressed as

their reciprocals (l/A, l/A'), theoretically yields a straight line
(figure d).

After irreversible inactivation of a fraction of recep-

tors, a small fraction (q) of receptors remain active.
effects require the same amount of receptor occupancy (E

Also, equal
2

f(AR)).

From these conditions, the following equation for the line obtained in
the double reciprocal plot is derived:
l/A

2

l/q • l/A

+

1-q/q • l/KA

where KA is the dissociation constant of the agonist.

The slope

of the line is the reciprocal value of the fraction of remaining
receptors (q).

The dissociation constant may be determined by

subtracting one from the slope and dividing the resulting value by the
y-intercept (see figure d).
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Figure d:

Double Reciprocal Plot of Equipotent Agonist Concentrations in
the Absence and Presence of Irreversible Receptor Blockade

msJ/q

..
y-int. =((1-q)/q) (l/K)
A

I/A'

'Illeoretical double reciprocal plot with slope of 1/q and
y-intercept of (1-q/q)(l/KA), obtained from partial irreversible receptor
blockade experiments. It "follows that the KA is slope-1/y-intercept.
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Agonist Affinity (l/KA):

Method of Partial Agonists

The method of partial agonists (Waud, 1969) makes use of the
large cardiac spare receptor capacity (Venter, 1979) and the fact that
partial agonists require greater receptor occupancy than full agonists.

Irreversible antagonists make full agonists act like partial

agonists, and thereby allow estimation of the full agonist's receptor
affinity.

Since a larger receptor occupancy is required, a partial

agonist may or may not elicit the tissue's maximum response.
In this method, one constructs dose-response curve for a full
agonist followed by a dose-response curve for the partial agonist,
after restoration of resting levels.

Figure 4 shows the concentration

of each agonist which produce equal responses yield agonist concentration pairs, (A1, P1) ••• (AN, PN) with A1 representing the full
agonist concentration and P1 representing the partial agonist concentration from only the linear portions of each line (Thron, 1970).
Plotting the reciprocal values of each agonist pair, (l/A, l/P),
yields a straight-line (figure f) having the following equation:

where A and P represents the full agonist and partial agonist
concentration, respectively.

The two terms KA and Kp represent

equilibrium dissociation constants for the full and partial agonists.
The value obtained by dividing the slope by the y-intercept yields the
equilibrium dissociation constant of the partial agonist (Kp):
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slope/y-intercept

eA/KA • Kp/ep
eA I epKA

after cancelling out like terms.

Kp
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Figure e:

Equal Response to a Full and Partial Agonist

E

p
Agonist Concentration
A

Curve I represents a dose-response curve to a full agonist.
Agonist concentrations, A , Ar., etc. produces an effect, E , E etc.
Partial agonist concentrations, P1 , P etc. from curve 11 1 yi~ld the same
2
effects, E1 , E etc. 'Illus, for egch effect,
there exists a pair of agonist
2
concentrations which can produce the same effect.

Figure f:

Double Reciprocal Plot of Equipotent Agonist Concentrations Using
Agonists with Different Efficacies

1/P

Equiactive agonist concentrations (Ai, Pi) yield reciprocal pairs
(l/A 1 , l/Pi) which yield the following line;
l/A • eA/ePKA + eA/KA • ~/ep • l/P
The quotient obtained by dividing the slope , by the y-intercept
yields the partial agonist dissociation constant (KP).
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MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats (7 weeks old) were obtained from Charles
River Breeding Labs (Wilmington, Mass.).

Unless otherwise indicated,

all animals were supplied with food (Purina Rat Chow) and water ad
libitum and housed under identical conditions throughout the 10-week
experimental period.
Experimental Grouping
The rats were divided into three main groups, designated control
(CT), streptozotocin-diabetic (STZ), and food restricted control (FR) •

..

The CT and STZ groups were divided into eight subgroups (1-8) and the
FR group into two subgroups (7-8) of at least 4 rats each.
restricted rats received two pellets of rat chow daily.

The food

Five of the

subgroups (1-5) were used for the study of competitive betaadrenoceptor blockade with each subgroup representing a different concentration of timolol maleate.

The sixth subgroup (6) was used for

the study of beta-adrenoceptor activation by the partial agonist,
metaproterenol.

The remaining subgroups (7-8) were used to study the

effect of the irreversible beta-adrenoceptor antagonist, Ro 03-7894.
The number of rats within each subgroup are shown in Table 1.

Table 1.

Experimental Grouping of Rats

Timolol Maleate Concentration(M)
-7.S __
10-8.S 10-8
10- 9
10
2
1
3
s
Group '-- SubgrouE
4

Partial Agonist

Irreversible Antagonist

As.corbate

6

7

Ro 03-7894
8

MetaEr.oterenol

(CT)

6

6

6

4

6

6

4

5

(STZ)

4

4

6

4

6

4

6

4

(FR)

-

-

-

-

-

-

4

4

This, table shows the grouping and number of rats used in the study of beta-adrenoceptors.
CT = Age-matched controls fed ad libitum; STZ = streptozotocin-induced diabetic animals; FR
age-matched food restricted controls fed 40 grams of rat chow daily. Subgroups 1-4 represent
timolol concentrations used in the study of reversible antagonism. Subgroup S was used as controls for both the reversible antagonism and partial agonist study. The partial agonist,
metaproterenol, was used with animals in subgroup 6. The remaining subgroups (7-8) were used
for the study of irreversible antagonism, ascorbate control and Ro 03-7894.

N

.....
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Induction of Diabetes
Diabetes was induced in rats with a single intravenous injection
of streptozotocin or STZ (40 mg/kg) into a tail vein (Rerup, 1970;
Like and Rossini, 1976; Ganda

~al,

1976).

The STZ was prepared in

0.1 M citrate buffer, pH 4.5 (40 mg/ml) immediately before injection.
About 75% of the animals injected with STZ became diabetic and exhibited glycosuria.

Animals which were injected with STZ, but did not

subsequently become diabetic,

were omitted from the study.

Age-

matched controls were injected with the citrate vehicle. Four to seven
days after injection, weekly metabolism and blood pressure recordings
were initiated.

Ten weeks after injection, the animals were sacri-

ficed.
Metabolism Studies
Beginning one week prior to injection, all rats were placed
singly into metabolism cages once a week for a period of 24 hours.
The following measurements were recorded:

urine output, the extent of

glycosuria using enzymatic test strips (Tes-Tape®, Lilly) body weight,
and food and water consumption.
Indirect Blood Pressure and Pulse Rate Measurement
Beginning two weeks prior to injection, systolic blood pressure
and pulse rates were measured weekly using an indirect tail-cuff
method.

The measurements were made after warming the rat at 34°C for

20 minutes in a temperature-controlled box.

An inflatable cuff was

placed around the base and a small bulb was placed on the distal portion of the tail.

The bulb was attached to a pneumatic pulse trans-
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ducer (MK III) which was coupled to an electrosphygmograph coupler
(Narco 7211) and an E & M type 4 physiograph.

Systolic arterial

pressure was obtained by inflating the tail cuff at pressures
exceeding 180 mm Hg, then noting the point at which the pulsations
reappeared during slow pressure reduction.

Pulse rates were recorded

simultaneously by determining the number of pulses per centimeter at a
set paper speed on the physiograph.

The mean of at least three

measurements was recorded for each animal.

The pressure was

calibrated at frequent intervals using a mercury column manometer.
Isolated Atria
Ten weeks after injection, the rats were killed by a blow to the
head.

The chest cavity was opened and the heart was rapidly removed

and placed in oxygenated buffer at ·room temperature.

A blood

sa~ple

was taken from the chest cavity for analysis of serum thyroxine and
glucose.

The blood sample was frozen in liquid nitrogen for later

analysis.
ventricles.

The left and right atria were surgically removed from the
The right atria were tied to tissue hangers by cotton

thread and the left atria were clamped to stimulating electrodes.
Both atria were vertically suspended in a 100 ml organ bath containing
Krebs-Henseleit buffer (composition in llii:

NaCl, 120; KCl, 5.6;

CaCl2·6H20, 2.4; NaH2P04, 1.21; MgS04•7H20, 1.33; Na2EDTA, 0.20;
NaHC03, 25; and glucose, 10) gassed with 5% C02 in oxygen at 37°C.
The atria were connected by cotton thread to a tension transducer;
Narco type A (0.1 - 3 gram sensitivity), and Narco type B (0.1 - 10
gram sensitivity) for right and left atria, respectively.

The

24

resulting tensions were recorded on an E & M type six physiograph.
Initial diastolic resting tensions of 0.8 and 0.5 grams were applied
to the left and the right atria, respectively.

Resting tensions were

determined from preliminary length-tension determinations.

The left

atria were driven at 2 HZ with square wave pulses (5 msec) at 1.5
times the threshold voltage by a Narco stimulator and the right atria
were allowed to beat spontaneously.

Tension (g) and rate (bpm)

changes were measured from the left and right atria, respectively.
Serum Analysis
Blood samples were thawed at room temperature and were allowed to
clot.

The clot was sedimented by centrifugation at 5000 g for 5 minu-

tes at 4°C.

The supernatant (serum) was decanted for analysis of

thyroxine and glucose.
state.

Hypothyroidism often accompanies the diabetic

An AmerlexN T-4 RIA kit was used to determine serum thyroxine

levels; the kit has a total range of 0 to 25 ug thyroxine/100 ml.
Serum was deproteinized with equinormal amounts of barium hydroxide
and zinc sulfate solutions prior to glucose determination.

The solu-

tion fraction was obtained by centrifugation at 5000 g for 10 minutes
and used for analysis of glucose.

Glucose was determined enzymati-

cally with glucose oxidase and peroxidase (Sigma Kit No. 510).

Serum

glucose was used to estimate the degree of the diabetic state.
Drug Addition
Left and right atria from non-diabetic (CT) and diabetic (STZ)
rats were allowed to stabilize for thirty minutes with frequent buffe!
changes.

The following protocol of drug administration was employed.
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Three cumulative dose-response curves were generated consecutively per
atrium.

Each curve was obtained by adding dl-isoproterenol directly

to the buffer, yielding concentrations ranging from lo-10 to lo-6 M,
in O.S log molar increments (Van Rossum, 1963).

The response to each

concentration of isoproterenol was allowed to stabilize prior to the
addition of the succeeding concentration (this stabilization period
never exceeded 60 seconds).

After the maximum responses were obained,

the atria were washed with drug-free buffer solution, at S minute
intervals for at least 30 minutes, to restore the tension or rate to
resting levels prior to the generation of the subsequent curve.

When

appropriate, the third curve was generated using the partial betaadrenoceptor agonist dl-metaproterenol, at concentrations between lo-8
and lo-4 M, instead of dl-isoproterenol.

Only the results of the

second and third curves were utilized, because previous studies have
shown that the slope of the first dose-response curve is different
from those of subsequent curves, and that the slopes of subsequent
curves are similar (Broadley and Lumley, 1977).
Antagonist drugs, when necessary, were added to the buffer prior
to generating the third dose-response curve.

timolol maleate was

added 40 minutes before, and was presenc throughout the generation of
the third dose-response curve.

Ro 03-7894 (3.2 x lo-4M) was added to

the bath for 30 minutes, then washed out with drug-free buffer for
four hours, prior to the generation of the third dose-response curve.
Parallel controls were exposed to an equivalent volume of the solution
used to dissolve the antagonist, but were otherwise treated iden-
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tically.

Stock solutions of isoproterenol, metaproterenol, and timo-

lol maleate were dissolved in 0.1 N HCl, and Ro 03-7894 in ascorbic
acid solution (1 mg/ml).

All drug dilutions were prepared fresh

daily, and kept on ice.
Resources
Drugs:

Instruments:

Timolol Maleate
Ro 03-7894
dl-Isoproterenol
dl-Metaproterenol
Streptozotocin

from
from
from
from
from

Merck, Sharpe & Dohme
Roche Products, Ltd.
Sigma Chemical Co.
Boehringer Ingelheim
Sigma Chemical Co.

E & M Type Six Physiograph
Narco Type A Tension Transducer
Narco Type B Tension Transducer
Narco Stimulator
Thermomix Circulation Pump and Heater
E & M (MK III) Pneumatic Pulse Transducer
Narco (7211) Electrosphygmyograph Coupler
E & M Type Four Physiograph

Serum
Analysis Kits:

Serum Glucose 510
from Sigma Chemical Co.
Amerlex T-4 RIA Kit from Amersham Corp.
DATA ANALYSIS

Plotting Dose-Response Curves
Responses were measured as the total rate or contraction frequency (bpm) and total developed tension (g) of the right and left
atria, respectively, at each agonist concentration.

Possible changes

in the sensitivity of right or left atria to the agonist between the
second and third curves which might occur in the absence of antagonist
drugs were accounted for using parallel control atria which were not
treated with the antagonist (Broadley and Nicholson, 1979).

Mean
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responses of untreated atria to each agonist concentration during the
generation of the third dose-response curve were expressed as a f raction of the mean responses to the equivalent agonist concentration
occurring during the generation of the second dose-response curve.
These fractions were then applied as correction factors for antagonist
treated atria.

The response to each agonist concentration during the

second dose-response curve was multipled by the appropriate correction
factor, to yield a corrected dose-response curve.

..

The effect of the

antagonist on the third curve was then determined by comparison with
the corrected second curve.
The responses were standardized to a percentage maximum response
scale.

Increases in rate or tension above the resting levels were

expressed as a percentage of the maximum increase.

This was calcu-

lated by dividing the individual increase in rate or · tension by the
maximum rate or tension increase and multiplying the resulting
quotient by

roo%.

Estimations of agonist potency (EC50 values) were calculated as
the negative log of the agonist concentration which produced half the
maximum response.

Arithmetic mean values of the EC50 are not normally

distributed (Fleming et al., 1972), but the logarithmic values are.
Therefore, pD2 values (-log EC50) were compared by the student's ttest for normal and diabetic atria.
Calculation of Antagonist Affinity by Using a Competitive BetaAdrenoceptor Antagonist:
pA2 values for the antagonism of isoproterenol-induced positive
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inotropic and positive chronotropic response by timolol maleate in
non-diabetic (CT) and diabetic (STZ) rat .atria were calculated by the
method of Arunlakshana and Schild (1959).

Dose-response curves were

obtained before and in the presence of one of four timolol mealeate
concentrations (10-9, 10-8.5, 10-8, and 10-7.5M).

Uncorrected respon-

ses, measured as the increase in tension or rate above resting levels
at each isoproterenol concentration, were expressed as a percentage of
their own maximum increase for both the second and third curves.
EC50

The

of each individual curve was then determined.
As described above, sensitivity changes not due to the antagonist

were corrected for by comparing the results obtained from control
experiments receiving no antagonist.

Any shift between the second and

third curve was expressed as a mean (n=6) correction factor (CF
(EC50, curve 3/EC50, curve z)ln.

=L

The individual EC50 values of the

second curves were corrected by multiplication by the mean correction
factor to yield a corrected EC50 value.

The corrected EC50 values

were used to obtain individual dose ratios (DR = EC50,curve 3/
corrected EC50,curvez).
values.

Each dose ratio was converted to log (DR-1)

The mean log (DR-1) values (± S.E) were plotted against the

negative log molar concentration of timolol maleate (-lOg B) for both
rate and tension responses.

Individual log (DR-1) and -log B points

were used to calculate a regression line (least squares analysis).
The values of slope, y-intercept, and x-intercept (pAz), with 95% confidence limits were calculated (Tallarida, 1979).

The pAz values for

both non-diabetic and diabetic rats were compared using an unpaired
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Student's t-test.
Estimation of AgOnist Affinity Using a Partial Beta-Adrenoceptor
Agonist:
Dissociation constants (Kp) for metaproterenol were calculated
for control (CT) and diabetic (STZ) rat atria by the method of partial
agonists described by Waud (1969).

The atria were exposed to cumula-

tive concentrations of isoproterenol twice with a washing in drug-free
buffer after each exposure to yield two dose-response curves.

A third

dose-response curve was constructed using cumulative concentrations of
metaproterenol.

The second dose-response curve was corrected as

described earlier (see "plotting dose-response curve").

The increases

in rate or tension in response to each isoproterenol concentration
were plotted as a percentage of the maximum increase.

The increases

in rate or tension in response to each metaproterenol concentration
were plotted as a percentage of the maximum possible increase, which
was calculated by subtracting the resting level prior to the third
dose-response curve from the corrected second dose-response curve
maximum total rate or tension.
Equiactive concentrations of isoproterenol (A) and metaproterenol
(P) obtained from the linear portion (Thron, ·1970) of each curve were
determined.

The reciprocal values for each atrium were plotted as

1/A versus l/p to yield the following line:
1/ A ..

eA •

i

•

l/p + eA

1

where eA and ep correspond to relative efficacy values for

30

isoproterenol and metaproterenol, respectively.
The dissociation constant (Kp) for metaproterenol equals the
slope divided by the intercept, which are obtained from linear
regression analysis.

Dissociation constants for diabetic and normal

atria were compared to an unpaired Student's t-test.
Estimation of Agonist Affinity Using An Irreversible Beta-Adrenoceptor
Antagonist:
Dissociation constants (KA) for isoproterenol were calculated for
normal (CT), diabetic (STZ) and food restricted (FR) rat atria by the
method of irreversible antagonism derived by Furchgott and Bursztyn
(1967).

Individual pre- (2nd curve) and post-antagonist (3rd curve)

dose-response curves were plotted as described earlier (see "plotting
dose-response curves") for total responses.

The increase in rate and

tension above the resting levels prior to each dose-response curve
were plotted as a percentage of the corrected second curve maximum
increase (the maximum possible increase).

This method avoids possible

misinterpretation arising from any change in the resting levels
induced by the antagonist.
Equiactive molar concentrations of isoproterenol obtained before
[A] and after washout of antagonist [A'] were determined from the
linear portion of the plot of % corrected second curve maximum
response versus the negative log concentration (M) of isoproterenol.
The mean reciprocal(± S.E.) values were plotted as l/A versus 1/A'.
The following equation was used to determine dissociation constants:
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1I A =

.!..:.9.. •
q

1

+ 1

KA

q

l/A'

where q is the fraction of remaining receptors unoccupied by Ro
03-7894.
Using linear regression analysis, the mean dissociation constants
(KA) and fraction of active receptors remaining (q) with 95% confidence limits were calculated as follows:
KA ,,.. [Slope- I) , q .. __l _
intercept
slope
Because constants for normal, diabetic, and food restricted rat
atria were compared using one way analysis of variance (Daniel, 1978).
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RESULTS
The Streptozotocin Diabetic Model*
Differences between streptozotocin-induced diabetic foodrestricted, and control animals are shown in Table 2.

The STZ-induced

diabetic rats exhibited reduced body weight, as did the foodrestricted rats though to a lesser extent, when compared to agematched control rats.

Polyuria, hyperglycemia, and glycosuria

accompanied the diabetic state, as well as, polydipsia and polyphagia
(data not shown).

The diabetic state significantly lowered serum

thyroxine levels compared to the food-restricted group.
thyroxine levels range from 3-4 ug/dl

(Fein~

produced a slight hypertension and bradycardia.

Normal

al., 1980).

Diabetes

There were no signi-

ficant differences between the potencies (pD2 values) for isoproterenol from control, food-restricted, and diabetic atria.
Figures 1-3 depict results from weekly monitoring of heart rate,
blood pressure, and body weight following the injection of streptozotocin or citrate vehicle.

Diabete~

produces significant changes

in all three (bradycardia, hypertension, and reduced body weight)
within three weeks after injection of streptozotocin and these changes
persist throughout the ten week experimental period.

* "Diabetes" will be used to describe the diabetic condition
induced by streptozotocin injection, with the implicit recognition
that chemically induced diabetes may differ in some respects from the
true diabetic state.
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Table 2:

Characteristics of Diabetic and Control Groups
CT

STZ

FR

BW

526 ± 16
(n=43)

413 ± 10*
(n=37)

464 ± 10*
(n=9)

Glu

239 ± 14
(n=20)

651 ± 37*
(n=21)

279 ± 48*
(n=5)

T-4
0.03 ± 0.01
(n=-23)

Urine
Urine Glu

0
(n=23)

1.22 ± 0.11**
(n=38)

2.41 ± 0.47
(n=8)

o.53 ± 0.05*
(n=12)

0.05 ± 0.01
(n=9)

2 +*
(n=12)

BP

136 ± 3
(n=23)

148 ± 2*
(n=12)

HR

376 ± 9
(n=23)

327 ± 11*
(n=12)

pD2
Iso

0
(n=9)

RA

8.37 ± 0.92
(n=43)

8.28 ± 0.58
(n=-37)

8.37 ± 0.26
(n=9)

LA

8.51 ± 0.53
(n=43)

8.62 ± 0.44
(n=37)

8.15 ± 0.22
(n=9)

Values represent mean ± 95% confidence intervals. Numbers in parentheses
represent the sample size. Asterisk (*) means that the value is significantly different (P (0.05) than the control value; the double
asterisks means that the value is significantly different than the food
restricted value.
Abbreviations
CT = Age-matched controls fed ad libitum; STZ = Streptozotocin-induced
diabetes, 10 weeks after the induction of diabetes; FR = Age-matched
controls on a food-restricted diet; BW = Body weight (grams; Glu = Serum
glucose levels (mg/ml); T-4 = Serum thyroxine levels (µg/dl);
Urine =Urine output (ml/g BW); Urine Glu =Urine glucose levels (%);
BP = Systolic blood pressure (mm Hg); HR= Heart rate (beats per
minute); pD2 =-log EC50 of the molar concentration of isoproterenol
producing half the maximal response; RA = Right atria; LA = Left atria.
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Figure 1:

Effect of SI'Z-Induced Diabetes on Heart Rate
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Time(weeks) after streptozotocin or citrate injection

8

Heart rates (± S.E.M.) taken weekly during the 10 week
experimental period from control ( e ) and diabetic ( • ) rats. A typical
age-dependent bradycardia developnent occurs in both groups with the diabetic
rats showing significant reductions within three weeks after injection of
streptozotocin. Asterisks represents significant differences from control
at P ~ 0.05. Nunbers in parentheses represent sample size. Time (weeks)
after streptozotocin or citrate vehicle lies on the abscissa. Heart rate
expressed as beats per minute (bpn) is shown on the ordinate.
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Figure 2:

Effect of srz-Induced Diabetes on Systolic Blood Pressure
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'Ihe mean systolic blood pressure (± S.E.M) taken
weekly during the JO week experimental period from control( ~ ) and
diabetic ( II ) rat.
A typical age-dependent elevation in blood
pressure occurs in both groups with the diabetic rats showing significant
elevations above control within two weeks after the injection of streptozotocin. Asterisks represent significant differences from control at P < 0.05.
Numbers i« parentheses represent sample size. Time (weeks) after streptozotocin or citrate vehicle injection lies on the abscissa. Systolic
blood pressure (lllTI Hg) is shown on the ordinate.
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Figure 3:

C"'l

BOdy weight (± S.E.M.) taken weekly for twelve
weeks. Auin~ls received streptozotocin (STZ) or citrate vehicle (CIT)
during the second week. Initiation of the food restriction regimen
occurred during the second week. Asterisks represent significant differences from control at P < O.OS. Numbers in parentheses represent
sample size. Time (weeks) Ties on the abscissa. Body weight (grams)
is shown on the ordinate. • = control;
8 = diabetic; .A. = food
restriction.
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Competitive Antagonism of the Responses to Isoproterenol by Timolol
Maleate
Figures 4 a-d depict the mean rate and tension dose-response curves to isoproterenol in the presence of increasing concentrations of
timolol maleate.

Increasing concentrations of timolol maleate (10-9,

10-8.5, lo-8, and 10-7.5 M) displaced the cumulative dose-response
curves (control and diabetic) to isoproterenol to the right in
parallel fashion without significantly (P
maximum response.
rates (P

~

~

0.05) depressing the

Diabetic right atria (figure 4c) had lower resting

0.001) than control right atria (figure 4a), but the maxi-

mum rates were not different.

Diabetes did not significantly affect

the resting or maximum developed tension of left atria (figures 4b and
d).

Figures 5 a-d show the mean increase in rate and tension above

resting levels, expressed as a percentage of the maximum possible
increase (determined by subtracting the resting level from the maximum
response obtained during the pre-antagonist dose-response curve), for
control and diabetic atria.

The dose-response curves for isoprotere-

nol exhibit parallel shifts to the right of the curve generated in the
absence of timolol maleate in a timolol maleate concentrationdependent manner.
Figures 6a and b depict Schild plots constructed from the mean
log (DR-1) values shown in Table 9 (see appendix) for right and left
atria, respectively.

Regression analysis of the individual log (DR-1)

values for the appropriate timolol maleate concentration yields the
pAz value and slope for each line.

Table 3 shows the mean pAz values
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(±

95% confidence interval) and slopes (± 95% confidence interval)

for each Schild plot shown in figures 6a and b.

Diabetes had no

effect on either the slope of the Schild plot or the estimate of antagonist binding affinity (pAz) in either right or left atria.

The

pes of the individual Schild plots do not vary significantly from
unity.

slo~
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Figure 4 a-d:

Effect of Tirnolol Maleate on the Absolute Response of NonDiabetic and Diabetic Rat Atria to Isoproterenol
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Figure 4 a-d:

Effect of Timolol Maleate on the Absolute Response of
Non-Diabetic and Diabetic Rat Atria to Isoproterenol

Mean cumulative dose-response curves (± S.E.M.) to dl-isoproterenol in the presence of various concentrations of timolol maleate
from control (a and b) and diabetic (c and d) rat atria. The curves
represent the mean rate (± E.E.M.) and tension (± S.E.M.) response at
each isoproterenol concentration. The mean diabetic resting rate (c)
is significantly (P <0.001) lower than the mean control resting rate
(a). A thirty minute incubation period without or with timolol
maleate preceded the generation of each curve. The concentrations of
timolol maleate: (•) no timolol maleate present, (o) lo-9 M, (•)
10-8.S M, ( D ) lo-8 M, and (A) lo-7 .S M. Numbers in parentheses
represent the sample size •

..
Figure 5 a-d:

Effect of Timolol Maleate on the Relative Response of
Non-Diabetic and Diabetic Rat Atria to Isoproterenol

Mean cumulative dose-response curves (± S.E.M.) to dl-isoproterenol in the presence of various concentrations of timolol maleate
from control (a and b) and diabetic (c and d) rat atria. The curves
represent the mean increase in rate (a and c) and tension (b and d)
above the resting levels plotted as a percentage of the maximum
increase for each isoproterenol concentration. Increasing timolol
maleate concentrations shift the dose-response curve to isoproterenol
further to the right without depressing the maximum response. The
concentrations of timolol maleate are: (•) no timolol maleate present, (o) 10-9 M, (•) lo-8.S M, (D) lo-8 M, and(&) lo-7.S M.
Numbers in parentheses represent the sample size.
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Figure 5 a-d:
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Effect of Timolol Maleate on the Re'lative Response of
Non-Diabetic and Diabetic Rat Atria to Isoproterenol
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Figure 6 a-b:

Effect of Diabetes on the Schild Plots of Rat Atrial Responses to
Isoproterenol in the Presence of Various Concentrations of
Timolol Maleate

J
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Schild plots from control ( e ) and diabetic( • ) rat atria, obtained
by plotting the mean log(DR-1) values (± S. E.M. ) from tables 3a and 3b versus
the negative logarithm of the timolol maleate concentration(M). Figure 6a
represents the right atria and figure 6b represents the left atria. Regression analysis of the Schild plots is depicted in table 4. Numbers in
parentheses represen t the sample size .
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Figure 6 a-~

Effect of Diabetes on the Schild Plots of Rat Atrial Responses t.o
I~oproterenol in the Presence of Various Concentrations of
TllllOlol Maleate
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Schild plots from control ( e ) and diabetic ( • ) rat atria, obtained
by plotting the mean log(DR-1) values (± S.E.M.) from tables 3a and Jb versus
the negative logarithm of the timolol maleate concentration(M). Figure 6a
represents the right atria and figure 6b represents the left atria. Regression analysis of the Schild plots is depicted in table 4. Numbers in
rxH·entheses represent the sample size .
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Table 3:

Schild Plot Analys i s
Left Atria

Right Atria

CT (n=22)
STZ (n=l8)

pA2

m

a_

9.13 ± 0.09
8.98 ± 0.12

1.16 ± 0.18
0.94 ± 0.21

8 .9S ± 0.03
9 .14 ± 0.21

m
1.18 ± 0 .2S
1.02 ± 0.40

Mean pA2 values (± 9S% confidence interval) of right and left
atria from control and diabetic rat atria. No significant differences
(P > O.OS) exist between the pA2 values from control and diabetic
atria. The mean slopes (± 9S% confidence interval) do not differ from
unity. The number in parentheses represent the sample size.
Irreversible Antagonism of the Responses to Isoproterenol by
Ro 03-7894

..

Ro 03-7894 (3.24 x lo-4 M) is used as an irreversible betaadrenoceptor antagonist, and displaces the dose-response curves to
isoproterenol to the right and reduces the maximum response (Nicholson
and Broadley, 1977).

Figures 7 a-f depict the mean dose-response cur-

ves, expressed as a percentage of the maximum possible increase, for
rate (a,c,e) and tension (b,d,f) from control (a and b), food
restricted (c and d), and diabetic (e and f) atria.

Ro 03-7894 signi-

ficantly reduced the resting rates and tensions (P ,S. O.OS) and reduced
the maximum rate and tension responses of rat atria to isoproterenol
(Table 4).

Neither diabetes nor food restriction significantly

altered the effects of Ro 03-7894 rat atrial dissociation constants
for isoproterenol (Table 4).

Therefore, neither diabetes nor food

restriction alters beta-adrenoceptor agonist binding affinity.

The

fraction of unoccupied receptors (q) were not significantly different
(P

> O.OS)

between experimental groups, but exhibited a high degree of

variability (Table 4).
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Table 4:

Antagonism by Ro 03-7894 and the Effect of Diabetes on the
Dissociation Constants for Isoproterenol
Group

Ri~ht

Atria
CT (n=6)
STZ (n=4)
FR (n=4)

% Max

KA (nM)

.9..

5.0
7.6
5.5

18.2 ± 15.4
15.3 ± 7.8
17.3 ± 5.4

.095 ± .030
.114 ± .051
.021 ± .004

33.8 ± 7.4
70.5 ± 12.0
40.0 ± 4.0

16.9 ± 5.3
26.8 ± 12.2
10.7 ± 3.5

.057 ± .026
.202 ± .090
.117 ± .023

60.8 ±
67.5 ±
56.0 ±

Left Atria
CT (n=6)
STZ (n=4)
FR (n=4)

Mean dissociation constants (± S.E.M.) for isoproterenol of cardiac beta-adrenoceptors. No significant differences (P >0.05) exist
between dissociation constants from control, food-restricted, and
diabetic atria. The fraction of unoccupied receptors (q) within
experimental groups are not significantly different (P >0.05). The
post-antagonist maximum responses (% max) are significantly (P (0.05)
reduced from the maximum possible response. Numbers in parentheses
represent sample size.
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Figure 7 a-f:

100

Effect of Ro 03-7894 on the Relative Response of Non-Diabetic,
Food Restricted, and Diabetic Rat Atria to Isoproterenol.
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Figure 7 a-f:

Effect of Ro 03-7894 on the Relative Response of
Non-Diabetic, Food-Restricted, and Diabetic Rat Atria
to Isoproterenol

Mean dose-response curves (± S.E.M.) to isoproterenol in the
absence (solid points) and presence (open points) of 3.24 x io-4 M
Ro 03-7894, after a 30 minute incubation period followed by a 4 hour
washout period. The presence of Ro 03-7894 displaces the doseresponse curve to the right and reduces the maximum response. Figures
a,c,e, represent the positive chronotropic response and figures b,d,f
represent the positive inotropic response to isoproterenol. Preantagonist curves were corrected from controls as described in text.
• = control animals, • = diabetic animals, & = food-restricted animals. Numbers in parentheses represent the sample size.
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Diabetic and Non-Diabetic Atrial Responsiveness to Isoproterenol and
to Metaproterenol
Metaproterenol produces parallel dose-response curves shifted to
the right of dose-response curves produced with isoproterenol.
Figures 8 a-d depict the mean dose-response curves obtained with
isoproterenol and then with metaproterenol producing the same maximum
response (Pi 0.05), but requiring higher concentrations to produce
the maximum response.
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Figure 8 a-d :

Relative Response of Non-Diabetic and Diabetic Rat
Atria to a Full (Isoproterenol) and Partial
(Metaproterenol) Agonist.

Mean cumulative dose-response curves (± S.E.M.) to isoproterenol
(solid symbols) and metaproterenol (open symbols) from control (a and
b) and diabetic (c and d) atria. The lines represent the mean
increase in rate (a and c) and tension (band d), plotted as a percentage of the maximum possible increase. The mean resting levels are
the same (P > 0.05) for the isoproterenol and metaproterenol. No
significant reduction (P > 0.05) in the maximum responses occur when
metaproterenol is the agonist. Table 6 contains the EC50 value for
each curve. Numbers in parentheses denote sample size •

..
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Figur e 8 a-d:
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The mean EC50 values of isoproterenol and metaproterenol for left
and right atria are compared in Table 5.

The EC50 values of metapro-

terenol are one hundred-fold higher than those of isoproterenol.
Table 5:

Comparison of Agonist Potencies (EC50 Values) between
Isoproterenol and Metaproterenol for the Positive
Chronotropic and Positive Inotropic Response for NonDiabetic and Diabetic Rat Atria
Right Atria
Iso2roterenol

CT ~n=S~
STZ n•4

(3.37 ± 0.6l)x10-§
3.77 ± 0.10 x10-

Meta2roterenol
(2.72 ± o.06)x10-j
2.70 ± a.so x10-

Left Atria
Isoproterenol
CT ~n=S~
STZ n•4

[3.25 ± o.s11x10-§
8.20 ± 1.21 x10-

Metaproterenol
[4.36 ± 0.43]x10-7
[S.33 ± l.OO]xl0-7

Mean EC50 values (± S.E.M.) of isoproterenol and metaproterenol,
obtained from control and diabetic atria. Isoproterenol is about one
hundred times more potent than metaproterenol. EC50 values from
diabetic atria do not differ significantly (P > 0.05) from control
atria. Numbers in parentheses denote sample size.
Individual experiments yielded pairs of agonist concentrations
which produce the same rate or tension response.

Plotting the

reciprocals of each pair as l/[isoproterenol] versus
l/[metaproterenol] for each experiment yields straight-lines.
Regression analysis of these lines provides values for the slope, yintercept, and correlation coefficient.

The quotient of the slope

divided by the y-intercept equals the dissociation constant for
metaproterenol.

Table 6 contains dissociation constants for metapro-

terenol from control and diabetic atria.

No significant differences
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(P

> 0.05)

were observed between control and diabetic atria.

does not alter metaproterenol binding affinity.

Diabetes

58

Table 6:

Effect of Diabetes on the Dissociation Constants for
Metaproterenol
IC

-11eta

(µM)

Right Atria

Left Atria

(n=5)

5.06 ± 3.24

0.50 ± 0.14

STZ (n=4)

5.20 ± 2.55

1.55 ± 1.49

CT

Mean dissociation constants (± S.E.M.) for metaproterenol binding
to beta-adrenoceptors from control and diabetic atria. No significant
differences (P >0.05) exist between dissociation constants from right
or left atria. Numbers in parentheses denote sample size.
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DISCUSSION
The results of the present study did not support the original
hypothesis that diabetes reduces beta-adrenoceptor agonist binding
affinity in rat atria.

These findings are in agreement with radioli-

gand binding studies recently reported by Ingebretson
and

Williams~

~al.

(1983)

al. (1983), showing that neither acute nor chronic

diabetes affected cardiac beta-adrenoceptor binding curves.
STZ-induced diabetes did not alter the estimated dissociation
constants for isoproterenol or metaproterenol in the present study.
The values for the dissociation constants for isoproterenol obtained
in the present study agree closely with those reported for guinea pig
atria (Table 7) and those of

Williams~

al. (1983),

using control

(51 ± 15 nM), food restricted (70 ± 11 nM), and STZ-induced diabetic
(78 ± 24 nM) rat hearts.

The value for the dissociation constants for

metaproterenol closely correspond with published values using guinea•
pig atria and different pharmacological techniques (Table 8).
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Table 7:

Dissociation Constants for Isoproterenol (Guinea Pig Atria)

~so

(nM)

Right Atria

Left Atria

Source

37.7 ± 14.5
(n=5)

28.0 ± 6.9
(n=8)

Broadley and Williams, 1982, 1983

a.

90.7 ± 36.0
(n=9)

84.7 ± 14.0
(n=9)

Broadley and McNeill, 1983

b.

29.0 ± 13.0
(n=4)

23.0 ± 7.0
(n=4)

c.

38.0 ± 18.0
(na4)

24.0 ± 23.0
(n:s4)

Broadley and Nicholson, 1980

Kiso values are the means ± S.E. mean calculated through the use
of irreversible receptor blockade by Ro 03-7894, (a) 7.6 x lo-4 M,
(b) 6.4 x lo-4 M, or (c) 3.24 x lo-4 M with a 3 hour washout period.
Numbers in parentheses denote sample size.

Table 8:

Dissociation Constants for Metaproterenol (Guinea Pig Atria)
K.

-Neta
Right Atria

(µM)

Left Atria

Source

8.4 ± 2.5
(n=6)

4.3 ± 1.3
(n=4)

Broadley and Williams, 1982, 1983

5.4 ± 2.1
(n=6)

7.6 ± 2.9
(n=8)

Williams and Broadley, 1983

4.2 ± 2.0*
(n=4)
10.0 ± 2.2
(n=4)

14.7 ± 8.3*
(n=4)
2.4 ± 1.3
(n=4)

Broadley and Nicholson, 1980

KMeta values are the means ± S.E. mean calculated through the use
of irreversible receptor blockade by Ro 03-7894 (7.6 x lo-4 M) with a
3 hour washout period. Asterisks signify the use of functional antagonism with carbachol to calculate the dissociation constant. Numbers
in parentheses denote sample size.
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Values for dissociation constants have a large variability
(Broadley and Nicholson, 1978).

This variability reduces the sen-

sitivity of statistical tests in distinguishing differences between
dissociation constants.

The magnitude of the variability in the pre-

sent study is similar to those reported in the studies cited in Table
8.

The estimations of the fraction of unoccupied receptors (q)
varied, which limits the ability to detect changes in betaadrenoceptor number.

There were no significant differences between

any of the estimates of the fraction of unoccupied receptors.
Furthermore, no specific trend in the estimates occurs:

for right

atria, the food restricted group had the lowest estimates (0.02), but
for left atria, the control group had the lowest estimates (0.057).
The irreversible antagonist, theoretically, inactivates the same
number of beta-adrenoceptors and a reduction in beta-adrenoceptor
number would be reflected by lower estimates of the fraction of unoccupied receptors.

If diabetes does reduce beta-adrenoceptor number,

then the estimations of the fraction of unoccupied receptors in diabetic atria should be lower than those in control atria.

However,

atrial size can influence the estimation of the fraction of unoccupied
beta-adrenoceptors, since a larger tissue will contain greater amounts
of beta-adrenoceptors, and atrial size was an uncontrolled variable.
The variations in atrial size limits the usefulness of the estimation
of the fraction of unoccupied receptors.
Diabetes does not alter antagonist binding affinity of cardiac
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beta-adrenoceptors.

Several radioligand binding studies (Savarese and

Berkowitz, 1980; Ingebretson

~al.,

1981;

Heyliger~

al., 1982)

demonstrate that chronic diabetes had no effect of [H3]-DHA binding
affinity in · rat ventricular tissues.

The present study confirms by

alternative methodology that antagonist binding affinity of cardiac
beta-adrenoceptors is not affected by diabetes.

The pA2 values for

timolol maleate from control and diabetic atria were not significantly
different from each other (Table 3).

The estimates of the pA2 values

are consistent with those found by other investigators (Dreyer and
Offermeier, 1980).

The pA2 value equals the negative logarithm of the

antagonist's dissociation constant when the slope of the Schild plot
is unity (Tallarida

~

None of the slopes of the Schild

al., 1979).

plots differed significantly from each other.

Thus, the antagonist

binding affinities are the ·same in control and diabetic atria.
Diabetes is a heterogenous disease state; other complications
such as hypothyroidism
Penpargkul

~al.,

(Fein~

1981; Malhorta

(Christlieb, 1973; Igarashi
Factor~

al •...L 1980;
~al.,

~al.,

Pittman~

al., 1981·;

1981), hypertension

1978; Kawashima et al., 1978;

al., 1981; Sasaki and Bunag, 1982; Hayashi et al., 1983) or

hypotension (Pfaffman, 1980; Jackson and Carrier, 1981; 1983), bradycardia (Savarese and Berkowitz, 1980) may accompany the diabetic
state.

In the present study, streptozotocin produced a diabetic state

characterized by glycosuria, polyuria, polyphagia, polydipsia, and
reduced body weight.

Bradycardia and a slight hypertensive effect

accompanied the diabetic condition.

The diabetic rats exhibited
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decreased serum thyroxine levels (hypothyrodism) and increased serum
glucose levels (hyperglycemia).
The presence of other disease states suggests that alterations in
the diabetic myocardium may not have a single underlying cause-andeffect relationship, but instead may be due to a multiplicity of factors.

It appears highly unlikely that streptozotocin itself could

have produced the reductions in beta-adrenoceptor number.
Streptozotocin is void of cardiotonic effects at a tissue and subcellular level (Fein .!:E. al., 1980; 1981).

However, hypothyroid ani-

mals have been shown to contain a decreased number of cardiac
beta-adrenoceptors with alterations in antagonist (DHA) binding affinity (Ciaraldi .!:E. al., 1977; Mcconnaughey .!:E. al., 1979; Chang .!:E. al.,
1982).

Ischac .!:E. al. (1983) found that hypothyroidism had not effect

on agonist potency (pAz), produced bradycardia, and had no effect on
maximum responses to isoproterenol.

Furthermore, in general, hyper-

tension can cause a reduction in beta-adrenoceptor number without
altering [H3]-DHA binding affinity (Williams .!:E. al., 1977; Woodcock .!:E.
al., 1979).

Because diabetes reduces both alpha- and beta-

adrenoceptor density and hypothyroidism increases alpha-adrenoceptor
density, Williams .!:E. al. (1983) discounts hypothyroidism as the primary cause of the reduction in beta-adrenoceptor density seen in
diabetes.

Furthermore, Williams et. al. (1983) found that diabetes

had no effect on muscarinic receptor number which suggests that
alterations in adrenergic receptors are specific.

Fein .!:E. al. (1980)

considers it unlikely that hypothyroidism produced the altered mecha-
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nics exhibited by diabetic papillary muscle because of the lack of
correlation between the free T4 index and the altered mechanical properties.

Bhalla~

al. (1980) found no difference in beta-

adrenoceptor number between control and spontaneously hypertensive
rats, instead they found a reduced affinity of beta-adrenoceptors for
isoproterenol.

The altered metabolic status of diabetic rats may also

produce changes in beta-adrenoceptor sensitivity.

Increased plasma

lipid content can reduce cardiac beta-adrenoceptor number without
affecting antagonist binding affinity (Wince and Rutledge, 1981).
Certain cardiac disease states such as ischaemia (Feuvray
1979) and heart failure

(Bristow~

~al.,

al., 1982) have been associated

with a reduction in beta-adrenoceptor number without alterations in
[H3]-DHA binding affinity.

It has already been noted that diabetics

have a higher incidence of mortality from heart disease than the nondiabetic population (Kannel, 1979).

Ischaemia and heart failure are

often the end results of heart disease.

Thus, diabetes may predispose

the heart to congestive heart failure in part by reducing betaadrenoceptor number without altering affinity.
Food restriction does not reproduce the cardiac alterations which
occur with diabetes
Malhorta

~al.,

(Fein~

1981).

al., 1980; Penpargkul

~al.,

1981;

The present study shows that caloric depriva-

tion induced by restricting food intake did not alter the dissociation
constants for isoproterenol.

Williams

~al.

(1983) also demonstrated

that caloric deprivation did not produce the alterations in betaadrenoceptors that occur in the diabetic state.
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In summary, the present study confirms that chronic diabetes does
not affect cardiac beta-adrenoceptor binding affinities for agonists
or antagonists.

Diabetes lowered the basal heart rate, but had no

affect on the maximum chronotropic responses to isoproterenol or
metaproterenol.

In addition, diabetes had no affect on agonist poten-

cies (EC50) for positive chronotropic and positive inotropic responses.

The methodology examined the maximum response and receptor

binding characteristics and did not quantitate the time course of the
response.

The reduced responsiveness to catecholamines in vivo may

result from a slower formation of agonist-receptor complexes due to
the reduction in beta-adrenoceptor number which has been demonstrated
by radioligand techniques (pharmacological techniques used in the present study cannot quantitate receptor number).

Thus, chronic diabetes

does not alter beta-adrenoceptor-drug binding characteristics, but may
influence the effect of drug-receptor binding.
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APPENDIX
Table 9 contains the mean EC50 values, obtained from corrected
pre-antagonist and post-antagonist dose-response curves to isoproterenol in the presence of different timolol maleate concentrations, and
the mean values of the logarithm (dose ratio minus one (± S.E.M.)),
obtained from the individual dose ratios from each set of atria.
table also includes the timolol maleate concentration (M) present
during the generation of the post-antagonist curve.

The
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Table 9:

Schild Plot Points from STZ-induced Diabetic and Normal
Rat Atria

Mean EC50 values from corrected pre-antogonist dose-response curves to isoproterenol (see "Plotting Dose-Response Curves") and from
post-antagonist dose-response curves to isoproterenol for each concentration of timolol maleate (M) for right and left atria. Corrected
pre-antogonist and post-antogonist EC50 values yield a dose ratio
(DR) for each timolol maleate concentration, which is converted to the
log (DR-1) value. The table shows the mean log (DR-1) values
(±S.E.M.), which represent the ordinate values for the Schild plot.
The values for both control (CT) and diabetic (STZ) atria are shown.
Numbers in parentheses denotes the sample size •

..
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Table 9:

Schild Plot Points from STZ-induced Diabetic and Normal
Rat Atria

Right Atria
Timolol Maleate
Concentration (M)
CT

lo-9

Mean EC50 (nM)
Corr. Pre-Antag.
Curve

Mean EC50 (nM)
Post-antag.
Curve

Mean log
(DR-1)

(n=6)

2.88

lo-8.5 (n.. 6)

1. 79

10.6

0.73 ± 0.09

lo-8

(n... 6)

2.93

57.4

1.21 ± 0.10

lo-7.5 (n:s6)

1.61

lo-9

(n=4)

3.48

6.55

0.09 ± 0.08

lo-8.5 (n=4)

2.85

9.04

0.36 ± 0.18

lo-8

(n•4)

5.23

40.3

0.84 ± 0.06

lo-7.5 (n--4)

2.12

74.3

1.51 ± 0.05

8.36

11.3

0 .08 ± 0.08

36.1

0.35 ± 0.13

5.89

152

0.20 ± 0.07

2 .oo ± 0.07

STZ

Left Atria
lo-9

(n,.6)

lo-8.5 (n... 6)

10.3

CT
lo-8

(n.. 6)

9.64

137

1.07 ± 0.06

lo-7.5 (n=6)

4.94

377

1.86 ± 0.04

----------~------------------------------------------------------

8.52

0.13 ± 0.07

(n.. 4)

7 .oo

lo-8.5 (n=4)

4.36

lo-8

(n.. 4)

6.46

151

1.22± 0.15

lo-7.5 (n=4)

5.12

576

1.62 ± 0 .36

lo-9

32.4

0.65 ± 0.22

STZ
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